A new tool to classify risk in patients with oral cavity squamous cell carcinoma.
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-10807097
This study is looking at tissue samples from patients with oral cavity squamous cell carcinoma to help figure out who might need extra treatments after surgery, so we can improve their chances of recovery.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10807097 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a histomorphometric risk classifier for patients diagnosed with oral cavity squamous cell carcinoma (OC-SCC). The approach involves analyzing tissue samples to better stratify patients into low, intermediate, or high-risk categories based on various clinical factors. By identifying patients who may benefit from additional treatments like post-operative radiation therapy or chemotherapy, the research aims to improve patient outcomes. The ultimate goal is to create a companion diagnostic tool that can guide treatment decisions more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with oral cavity squamous cell carcinoma, particularly those undergoing surgical treatment.
Not a fit: Patients with other types of cancers or those not diagnosed with oral cavity squamous cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for patients with OC-SCC, potentially improving survival rates.
How similar studies have performed: Previous research has shown success in using histomorphometric analysis for cancer risk stratification, indicating that this approach has potential for meaningful advancements.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MADABHUSHI, ANANT — EMORY UNIVERSITY
- Study coordinator: MADABHUSHI, ANANT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: American Cancer Society, American Joint Committee on Cancer